Viewing Study NCT06371781



Ignite Creation Date: 2024-05-06 @ 8:24 PM
Last Modification Date: 2024-10-26 @ 3:27 PM
Study NCT ID: NCT06371781
Status: COMPLETED
Last Update Posted: 2024-04-22
First Post: 2024-04-04

Brief Title: Examination of the Relationship Between Weight Gain During Pregnancy and Sfrp-5 Netrin-4 and Resistin Concentrations
Sponsor: Cumhuriyet University
Organization: Cumhuriyet University

Study Overview

Official Title: Examination of the Relationship Between Sfrp-5 Netrin-4 and Resistin Concentrations in Maternal Blood Samples and Weight Gain During Pregnancy
Status: COMPLETED
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Researchers thought that the molecules Sfrp-5 Resistin and Netrin-4 which will be examine they may have a significant effect on weight gain during pregnancy Based on these foundations researchers expect changes in the levels of these molecules in women who gain excessive weight during pregnancy In this study researchers aimed to examine the moderator relationship between the molecules will be examine and weight gain in women who gained weight above the normal limits determined during pregnancy For this reason 44 participant who gained excessive weight during pregnancy and 46 pregnant participant who gained normal weight were included in the study The levels of Netrin-4 Sfrp-5 and Resistin molecules in the blood serum of the individuals in the study group were measured with a Commercial Elisa kit
Detailed Description: In this study researchers aimed to examine the moderator relationship between molecules such as Netrin-4 Sfrp-5 and Resistin and weight gain in participant with weight gain above the normal limits determined during pregnancy

Pregnant participants who were given birth at Cumhuriyet University Faculty of Medicine Hospital Gynecology and Obstetrics Clinic between July 1 2021 and July 1 2022 and whose pregnancy follow-ups were performed in our hospital were included in this prospectively designed study This study was divided into two main groups the first group will consist of pregnant participant with above-normal weight gain during pregnancy n 44 and the other group will consist of pregnant participant with normal weight gain during pregnancy n 46 In the study individuals who agreed to participate in the study were first asked to fill out a form containing demographic data such as age education pre- and postnatal height and weight

To ensure consistency in womens care these new Institute of Medicine IOM 2009 guidelines are based on BMI cutoffs developed by the World Health Organization and adopted by the National Heart Lung and Blood Institute Weight distribution according to BMI ranges 185 kgm2 underweight 185-249 kgm2 normal weight 25-299 kgm2 overweight and 30 kgm2 obese According to these guidelines the recommended weight gain range for underweight UW women is 125-18 kg for normal weight NW women 115-16 kg and overweight women OW 7-115 kg obese OB women are recommended to gain only 5-9 kg during pregnancy These values according to the IOM-2009 guideline are the most widely accepted recommendations for weight gain during pregnancy Weight gain above these values researchers have specified will be considered as excessive weight gain for usThe levels of these molecules in the serum of the study groups were measured using a commercial ELISA kit

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
1919B012108892 OTHER_GRANT TUBITAK None